Similar articles

• [Rimonabant (Acomplia)].

  Duh D, Vanddevijver A. Duh D, et al. J Pharm Belg. 2008 Mar;63(1):27-8. J Pharm Belg. 2008. PMID: 18479080 French. No abstract available.
• Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.

  Patel KN, Joharapurkar AA, Patel V, Kshirsagar SG, Bahekar R, Srivastava BK, Jain MR. Patel KN, et al. Can J Physiol Pharmacol. 2014 Dec;92(12):975-83. doi: 10.1139/cjpp-2014-0310. Epub 2014 Sep 29. Can J Physiol Pharmacol. 2014. PMID: 25361428
• [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].

  Ducobu J, Sternon J. Ducobu J, et al. J Pharm Belg. 2005;60(3):89-91. J Pharm Belg. 2005. PMID: 16252510 Review. French.
• Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?

  Di Marzo V. Di Marzo V. Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):610-2. doi: 10.1038/ncpcardio1319. Epub 2008 Aug 12. Nat Clin Pract Cardiovasc Med. 2008. PMID: 18695695 No abstract available.
• An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.

  Christopoulou FD, Kiortsis DN. Christopoulou FD, et al. J Clin Pharm Ther. 2011 Feb;36(1):10-8. doi: 10.1111/j.1365-2710.2010.01164.x. J Clin Pharm Ther. 2011. PMID: 21198716 Review.